All In Biotech

Drug Trial Radar · NCT07817706

Development of a Noninvasive Metric to Measure Small Bowel Sensation - The Small Intestine Stress Test

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jun 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this research is to identify the concentration of mannitol solution (a type of sugar alcohol) that will generate a range of symptoms in individuals without Disorders of Gut Brain Interaction (DGBI) to establish the normative range of responses to small bowel (SB) distension.

Conditions

  • Disorders of Gut Brain Interaction

Interventions

  • Mannitol Solution 76 mOsm/LDrug

    Participants will ingest 500 mL of mannitol solution at 76 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.

  • Mannitol Solution 189 mOsm/LDrug

    Participants will ingest 500 mL of mannitol solution at 189 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.

  • Mannitol Solution 325 mOsm/LDrug

    Participants will ingest 500 mL of mannitol solution at 325 mOsm/L radiolabeled with 111Indium-DTPA during one testing visit.

  • ScintigraphyDiagnostic test

    Scintigraphy will be used to track gastric emptying, small bowel transit, and colonic filling of the radiolabeled mannitol solution during each testing visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Gastrointestinal Symptom Severity During Small Bowel Transit Following 76 mOsm/L Mannitol Solution IngestionTime frame: At baseline and at 15-minute intervals beginning 30 minutes after ingestion through 180 minutes post-ingestion.
  2. Peak Gastrointestinal Symptom Severity During Small Bowel Transit Following 189 mOsm/L Mannitol Solution IngestionTime frame: At baseline and at 15-minute intervals beginning 30 minutes after ingestion through 180 minutes post-ingestion.
  3. Peak Gastrointestinal Symptom Severity During Small Bowel Transit Following 325 mOsm/L Mannitol Solution IngestionTime frame: At baseline and at 15-minute intervals beginning 30 minutes after ingestion through 180 minutes post-ingestion.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.